Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CTAD 2022

Nov 29-Dec 2, San Francisco, CA.

 

Every year, the Clinical Trials on Alzheimer’s Disease conference (CTAD) brings together leaders in academia and industry to share and debate the latest in Alzheimer’s disease therapeutic trials. CTAD 2022 featured highly anticipated late-phase research news, as well as introductions to novel agents, ongoing studies, and cutting-edge clinical trial strategies.

Explore our coverage below!

Popular new uploads

View all
2:10
FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?
Alvaro Pascual-Leone • 9 Jan 2023
2:41
Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease
Carla Abdelnour • 29 Nov 2022
3:06
The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia
Hussein Yassine • 30 Nov 2022
4:37
Long-term transdermal nicotine for the treatment of mild cognitive impairment
Paul Newhouse • 23 Nov 2022

Lecanemab news

View all
5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain • 6 Dec 2022
5:24
Lecanemab: a review
Alvaro Pascual-Leone • 9 Jan 2023

Novel treatments

View all
7:29
New pivotal study using photobiomodulation in Alzheimer’s treatment
Jacques Touchon • 9 Dec 2022
3:53
Nilotinib: a potential repurposed treatment for Alzheimer’s disease?
Charbel Moussa • 28 Nov 2022

Improving diagnosis & prognostication

View all
2:52
Speech biomarker for cognition: a novel marker for AD clinical trial screening
Nicklas Linz • 8 Dec 2022
3:37
The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD
Paul Kinnon • 21 Nov 2022
6:13
Biomarkers for early detection of Alzheimer’s disease: microRNAs
Bruno Steinkraus • 1 Dec 2022
5:34
Associations between predicted brain age and Alzheimer’s Disease biomarkers
Irene Cumplido-Mayoral • 25 Nov 2022
The content of VJDementia is intended for healthcare professionals